1
|
Wu Y, Zhao D, Shang J, Huang W, Chen Z. A novel star-shaped trinuclear platinum(II) complex based on a 1,3,5-triazine core displaying potent antiproliferative activity against TNBC by the mitochondrial injury and DNA damage mechanism. Dalton Trans 2022; 51:10930-10942. [PMID: 35731536 DOI: 10.1039/d2dt00895e] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Polynuclear platinum(II) complexes represent a class of great prospective Pt-based antitumor drugs that may expand the antitumor spectrum and overcome the clinical problems of drug resistance and side effects of platinum-based drugs. Herein, a novel star-shaped trinuclear platinum(II) complex [Pt3(L-3H)Cl3] (1, L = 2,4,6-tris[(2-hydroxybenzyl)(2-pyridylmethyl)amine]-1,3,5-triazine) and its monomer [Pt(L'-H)Cl] (2, L' = (2-hydroxybenzyl)(2-pyridylmethyl)amine) were synthesized and characterized. The in vitro antiproliferative activities of complexes 1 and 2 against a panel of human cancer cell lines including MDA-MB-231 (triple-negative breast cancer, TNBC), MCF-7 (breast), HepG-2 (liver), and A549 (lung) were investigated. The results revealed that 1 exhibited much higher antiproliferative properties than its monomer 2 against the tested cell lines. Importantly, 1 possessed 3.3-fold higher antiproliferative activity as compared with cisplatin against the TNBC cell line MDA-MB-231. Another TNBC cell line MDA-MB-468 is also sensitive to 1. The results indicated that 1 might have the potential to act as a candidate for the treatment of TNBC. Cellular uptake and distribution studies showed that 1 could pass through the membrane of cells and enter into cells and mainly accumulate in the nuclei and mitochondria. 1 could bind to DNA in a cooperative groove-electrostatic-platinating binding mode and induce stronger DNA double-strand breaks (DSBs) and damaging effects on MDA-MB-231 than cisplatin (upregulation of γ-H2AX). Moreover, the DNA damage could not be easily repaired (upregulation of p53), which would exert a much positive influence on the overcoming of drug resistance. Additionally, flow cytometry studies showed that 1 arrested the cell cycle in the G0/G1 phase, induced mitochondrial membrane depolarization, increased ROS generation, and induced cell apoptosis. The results demonstrated that 1 could target simultaneously mitochondria and nuclei that gave rise to mitochondrial injury and DNA damage and ultimately efficiently promote the apoptotic death of tumor cells. Further mechanistic studies showed that 1 induced MDA-MB-231 cell apoptosis via the p53-mediated mitochondrial pathway by upregulating Bax and cytochrome c and downregulating Bcl-2 proteins, leading to the activation of caspase-3 and upregulation of the cleaved-PARP level. Taken together, 1 with such a synergic mechanism has great potential to be an effective anticancer agent that can overcome treatment resistance in TNBC.
Collapse
Affiliation(s)
- Yixuan Wu
- Key Laboratory of Optoelectronic Chemical Materials and Devices of Ministry of Education, School of Optoelectronic Materials and Technologies, Jianghan University, Wuhan 430056, P. R. China.
| | - Dandan Zhao
- Key Laboratory of Optoelectronic Chemical Materials and Devices of Ministry of Education, School of Optoelectronic Materials and Technologies, Jianghan University, Wuhan 430056, P. R. China.
| | - Jinting Shang
- Wuhan Institutes of Biomedical Sciences, School of Medicine, Jianghan University, Wuhan 430056, P. R. China
| | - Wenxin Huang
- Key Laboratory of Optoelectronic Chemical Materials and Devices of Ministry of Education, School of Optoelectronic Materials and Technologies, Jianghan University, Wuhan 430056, P. R. China.
| | - Zhanfen Chen
- Key Laboratory of Optoelectronic Chemical Materials and Devices of Ministry of Education, School of Optoelectronic Materials and Technologies, Jianghan University, Wuhan 430056, P. R. China. .,Wuhan Institutes of Biomedical Sciences, School of Medicine, Jianghan University, Wuhan 430056, P. R. China
| |
Collapse
|
2
|
Peng K, Liang BB, Liu W, Mao ZW. What blocks more anticancer platinum complexes from experiment to clinic: Major problems and potential strategies from drug design perspectives. Coord Chem Rev 2021. [DOI: 10.1016/j.ccr.2021.214210] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
3
|
Andrezálová L, Országhová Z. Covalent and noncovalent interactions of coordination compounds with DNA: An overview. J Inorg Biochem 2021; 225:111624. [PMID: 34653826 DOI: 10.1016/j.jinorgbio.2021.111624] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 08/30/2021] [Accepted: 09/28/2021] [Indexed: 12/26/2022]
Abstract
Deoxyribonucleic acid plays a central role in crucial cellular processes, and many drugs exert their effects through binding to DNA. Since the discovery of cisplatin and its derivatives considerable attention of researchers has been focused on the development of novel anticancer metal-based drugs. Transition metal complexes, due to their great diversity in size and structure, have a big potential to modify DNA through diverse types of interactions, making them the prominent class of compounds for DNA targeted therapy. In this review we describe various binding modes of metal complexes to duplex DNA based on covalent and noncovalent interactions or combination of both. Specific examples of each binding mode as well as possible cytotoxic effects of metal complexes in tumor cells are presented.
Collapse
Affiliation(s)
- Lucia Andrezálová
- Institute of Medical Chemistry, Biochemistry and Clinical Biochemistry, Faculty of Medicine, Comenius University, Sasinkova 2, 813 72 Bratislava, Slovakia; Department of Inorganic Chemistry, Faculty of Natural Sciences, Comenius University, Mlynská dolina, Ilkovičova 6, 842 15 Bratislava, Slovakia.
| | - Zuzana Országhová
- Institute of Medical Chemistry, Biochemistry and Clinical Biochemistry, Faculty of Medicine, Comenius University, Sasinkova 2, 813 72 Bratislava, Slovakia
| |
Collapse
|
4
|
Yousuf I, Bashir M, Arjmand F, Tabassum S. Advancement of metal compounds as therapeutic and diagnostic metallodrugs: Current frontiers and future perspectives. Coord Chem Rev 2021. [DOI: 10.1016/j.ccr.2021.214104] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
5
|
Valente A, Podolski-Renić A, Poetsch I, Filipović N, López Ó, Turel I, Heffeter P. Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance. Drug Resist Updat 2021; 58:100778. [PMID: 34403910 DOI: 10.1016/j.drup.2021.100778] [Citation(s) in RCA: 35] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 06/18/2021] [Accepted: 08/03/2021] [Indexed: 12/19/2022]
Abstract
Drug resistance remains the major cause of cancer treatment failure especially at the late stage of the disease. However, based on their versatile chemistry, metal and metalloid compounds offer the possibility to design fine-tuned drugs to circumvent and even specifically target drug-resistant cancer cells. Based on the paramount importance of platinum drugs in the clinics, two main areas of drug resistance reversal strategies exist: overcoming resistance to platinum drugs as well as multidrug resistance based on ABC efflux pumps. The current review provides an overview of both aspects of drug design and discusses the open questions in the field. The areas of drug resistance covered in this article involve: 1) Altered expression of proteins involved in metal uptake, efflux or intracellular distribution, 2) Enhanced drug efflux via ABC transporters, 3) Altered metabolism in drug-resistant cancer cells, 4) Altered thiol or redox homeostasis, 5) Altered DNA damage recognition and enhanced DNA damage repair, 6) Impaired induction of apoptosis and 7) Altered interaction with the immune system. This review represents the first collection of metal (including platinum, ruthenium, iridium, gold, and copper) and metalloid drugs (e.g. arsenic and selenium) which demonstrated drug resistance reversal activity. A special focus is on compounds characterized by collateral sensitivity of ABC transporter-overexpressing cancer cells. Through this approach, we wish to draw the attention to open research questions in the field. Future investigations are warranted to obtain more insights into the mechanisms of action of the most potent compounds which target specific modalities of drug resistance.
Collapse
Affiliation(s)
- Andreia Valente
- Centro de Química Estrutural and Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, Lisboa, Portugal
| | - Ana Podolski-Renić
- Department of Neurobiology, Institute for Biological Research "Siniša Stanković" - National Institute of Republic of Serbia, University of Belgrade, Serbia
| | - Isabella Poetsch
- Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Nenad Filipović
- Department of Chemistry and Biochemistry, Faculty of Agriculture, University of Belgrade, Belgrade, Serbia
| | - Óscar López
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Sevilla, Spain
| | - Iztok Turel
- Faculty of Chemistry and Chemical Technology, University of Ljubljana, Ljubljana, Slovenia
| | - Petra Heffeter
- Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
| |
Collapse
|
6
|
Kuijpers T, Blom B. Homo and heterobimetallic palladium and platinum complexes bearing μ-diphosphane bridges involved in biological studies. Eur J Med Chem 2021; 223:113651. [PMID: 34214843 DOI: 10.1016/j.ejmech.2021.113651] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 06/10/2021] [Accepted: 06/13/2021] [Indexed: 02/03/2023]
Abstract
Given the increasing reports of well-defined bimetallic molecular complexes as potential anticancer agents in the last decades, along with the prevalence of platinum in anticancer therapy, we report here a detailed survey of bimetallic platinum and palladium complexes investigated as potential anticancer agents. Specifically, we will concentrate on the synthesis, characterisation and biological (anticancer) studies of a sub-class of these agents, namely homo and heterobimetallic complexes bearing a bridging phosphane ligand of the type: [LnM1(μ-R2P(CH2)nPR2)M2Lm] (where M1 is platinum or palladium, M2 is any other transition metal, R = alkyl or aryl substituents, Ln or Lm are co-ligands, n = 1-6). We will review the in vitro and in vivo activities and any mechanistic anticancer studies of these complexes with a view of trying to delineate patterns in biological activity and structure-activity relationships (SAR). We do not include the review of bimetallic complexes in this class that have not undergone any anticancer testing, nor those that have been involved in other biological investigations unrelated to cancer studies.
Collapse
Affiliation(s)
- Talita Kuijpers
- Maastricht Science Programme, Faculty of Science and Engineering, Maastricht University, Paul-Henri Spaaklaan, 1, PO Box 616, 6200 MD, Maastricht, the Netherlands
| | - Burgert Blom
- Maastricht Science Programme, Faculty of Science and Engineering, Maastricht University, Paul-Henri Spaaklaan, 1, PO Box 616, 6200 MD, Maastricht, the Netherlands.
| |
Collapse
|
7
|
Köberle B, Schoch S. Platinum Complexes in Colorectal Cancer and Other Solid Tumors. Cancers (Basel) 2021; 13:cancers13092073. [PMID: 33922989 PMCID: PMC8123298 DOI: 10.3390/cancers13092073] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 04/22/2021] [Accepted: 04/23/2021] [Indexed: 12/25/2022] Open
Abstract
Simple Summary Cisplatin is successfully used for the treatment of various solid cancers. Unfortunately, it shows no activity in colorectal cancer. The resistance phenotype of colorectal cancer cells is mainly caused by alterations in p53-controlled DNA damage signaling and/or defects in the cellular mismatch repair pathway. Improvement of platinum-based chemotherapy in cisplatin-unresponsive cancers, such as colorectal cancer, might be achieved by newly designed cisplatin analogues, which retain activity in unresponsive tumor cells. Moreover, a combination of cisplatin with biochemical modulators of DNA damage signaling might sensitize cisplatin-resistant tumor cells to the drug, thus providing another strategy to improve cancer therapy. Abstract Cisplatin is one of the most commonly used drugs for the treatment of various solid neoplasms, including testicular, lung, ovarian, head and neck, and bladder cancers. Unfortunately, the therapeutic efficacy of cisplatin against colorectal cancer is poor. Various mechanisms appear to contribute to cisplatin resistance in cancer cells, including reduced drug accumulation, enhanced drug detoxification, modulation of DNA repair mechanisms, and finally alterations in cisplatin DNA damage signaling preventing apoptosis in cancer cells. Regarding colorectal cancer, defects in mismatch repair and altered p53-mediated DNA damage signaling are the main factors controlling the resistance phenotype. In particular, p53 inactivation appears to be associated with chemoresistance and poor prognosis. To overcome resistance in cancers, several strategies can be envisaged. Improved cisplatin analogues, which retain activity in resistant cancer, might be applied. Targeting p53-mediated DNA damage signaling provides another therapeutic strategy to circumvent cisplatin resistance. This review provides an overview on the DNA repair pathways involved in the processing of cisplatin damage and will describe signal transduction from cisplatin DNA lesions, with special attention given to colorectal cancer cells. Furthermore, examples for improved platinum compounds and biochemical modulators of cisplatin DNA damage signaling will be presented in the context of colon cancer therapy.
Collapse
Affiliation(s)
- Beate Köberle
- Department of Food Chemistry and Toxicology, Karlsruhe Institute of Technology, Adenauerring 20a, 76131 Karlsruhe, Germany
| | - Sarah Schoch
- Department of Laboratory Medicine, Lund University, Scheelevägen 2, 223 81 Lund, Sweden
| |
Collapse
|
8
|
Steel TR, Tong KK, Söhnel T, Jamieson SM, Wright LJ, Crowley JD, Hanif M, Hartinger CG. Homodinuclear organometallics of ditopic N,N-chelates: Synthesis, reactivity and in vitro anticancer activity. Inorganica Chim Acta 2021. [DOI: 10.1016/j.ica.2020.120220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
9
|
Masaryk L, Koczurkiewicz-Adamczyk P, Milde D, Nemec I, Słoczyńska K, Pękala E, Štarha P. Dinuclear half-sandwich Ir(III) complexes containing 4,4′-methylenedianiline-based ligands: Synthesis, characterization, cytotoxicity. J Organomet Chem 2021. [DOI: 10.1016/j.jorganchem.2021.121748] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
10
|
Kumar M, Lal N, Luthra PM, Masram DT. Exploring the binding and cleavage activities of nickel II complexes towards DNA and proteins. NEW J CHEM 2021. [DOI: 10.1039/d0nj06210c] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Three novel nickel(ii) complexes with cis octahedral geometry display excellent binding and cleavage affinity towards DNA and proteins. Furthermore, all complexes show superior cytotoxicity against human lung (A549) and breast (MCF-7) tumor cells.
Collapse
Affiliation(s)
- Manish Kumar
- Department of Chemistry
- University of Delhi
- Delhi-110007
- India
| | - Neetika Lal
- Dr. B.R. Ambedkar Centre for Biomedical Research
- University of Delhi
- Delhi-110007
- India
| | - Pratibha Mehta Luthra
- Dr. B.R. Ambedkar Centre for Biomedical Research
- University of Delhi
- Delhi-110007
- India
| | | |
Collapse
|
11
|
Studer V, Anghel N, Desiatkina O, Felder T, Boubaker G, Amdouni Y, Ramseier J, Hungerbühler M, Kempf C, Heverhagen JT, Hemphill A, Ruprecht N, Furrer J, Păunescu E. Conjugates Containing Two and Three Trithiolato-Bridged Dinuclear Ruthenium(II)-Arene Units as In Vitro Antiparasitic and Anticancer Agents. Pharmaceuticals (Basel) 2020; 13:E471. [PMID: 33339451 PMCID: PMC7767221 DOI: 10.3390/ph13120471] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Revised: 12/10/2020] [Accepted: 12/11/2020] [Indexed: 12/15/2022] Open
Abstract
The synthesis, characterization, and in vitro antiparasitic and anticancer activity evaluation of new conjugates containing two and three dinuclear trithiolato-bridged ruthenium(II)-arene units are presented. Antiparasitic activity was evaluated using transgenic Toxoplasmagondii tachyzoites constitutively expressing β-galactosidase grown in human foreskin fibroblasts (HFF). The compounds inhibited T.gondii proliferation with IC50 values ranging from 90 to 539 nM, and seven derivatives displayed IC50 values lower than the reference compound pyrimethamine, which is currently used for treatment of toxoplasmosis. Overall, compound flexibility and size impacted on the anti-Toxoplasma activity. The anticancer activity of 14 compounds was assessed against cancer cell lines A2780, A2780cisR (human ovarian cisplatin sensitive and resistant), A24, (D-)A24cisPt8.0 (human lung adenocarcinoma cells wild type and cisPt resistant subline). The compounds displayed IC50 values ranging from 23 to 650 nM. In A2780cisR, A24 and (D-)A24cisPt8.0 cells, all compounds were considerably more cytotoxic than cisplatin, with IC50 values lower by two orders of magnitude. Irrespective of the nature of the connectors (alkyl/aryl) or the numbers of the di-ruthenium units (two/three), ester conjugates 6-10 and 20 exhibited similar antiproliferative profiles, and were more cytotoxic than amide analogues 11-14, 23, and 24. Polynuclear conjugates with multiple trithiolato-bridged di-ruthenium(II)-arene moieties deserve further investigation.
Collapse
Affiliation(s)
- Valentin Studer
- Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland; (V.S.); (O.D.); (T.F.)
| | - Nicoleta Anghel
- Vetsuisse Faculty, Institute of Parasitology, University of Bern, Länggassstrasse 122, CH-3012 Bern, Switzerland; (N.A.); (G.B.); (Y.A.); (J.R.)
| | - Oksana Desiatkina
- Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland; (V.S.); (O.D.); (T.F.)
| | - Timo Felder
- Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland; (V.S.); (O.D.); (T.F.)
| | - Ghalia Boubaker
- Vetsuisse Faculty, Institute of Parasitology, University of Bern, Länggassstrasse 122, CH-3012 Bern, Switzerland; (N.A.); (G.B.); (Y.A.); (J.R.)
| | - Yosra Amdouni
- Vetsuisse Faculty, Institute of Parasitology, University of Bern, Länggassstrasse 122, CH-3012 Bern, Switzerland; (N.A.); (G.B.); (Y.A.); (J.R.)
- Laboratoire de Parasitologie, Institution de la Recherche et de l’Enseignement Supérieur Agricoles, École Nationale de Médecine Vétérinaire de Sidi Thabet, University of Manouba, Sidi Thabet 2020, Tunisia
| | - Jessica Ramseier
- Vetsuisse Faculty, Institute of Parasitology, University of Bern, Länggassstrasse 122, CH-3012 Bern, Switzerland; (N.A.); (G.B.); (Y.A.); (J.R.)
| | - Martin Hungerbühler
- Department of BioMedical Research, Experimental Radiology, University of Bern, CH-3008 Bern, Switzerland; (M.H.); (C.K.); (J.T.H.)
- Department of Diagnostic, Interventional and Pediatric Radiology, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland
| | - Christoph Kempf
- Department of BioMedical Research, Experimental Radiology, University of Bern, CH-3008 Bern, Switzerland; (M.H.); (C.K.); (J.T.H.)
- Department of Diagnostic, Interventional and Pediatric Radiology, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland
| | - Johannes Thomas Heverhagen
- Department of BioMedical Research, Experimental Radiology, University of Bern, CH-3008 Bern, Switzerland; (M.H.); (C.K.); (J.T.H.)
- Department of Diagnostic, Interventional and Pediatric Radiology, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland
| | - Andrew Hemphill
- Vetsuisse Faculty, Institute of Parasitology, University of Bern, Länggassstrasse 122, CH-3012 Bern, Switzerland; (N.A.); (G.B.); (Y.A.); (J.R.)
| | - Nico Ruprecht
- Department of BioMedical Research, Experimental Radiology, University of Bern, CH-3008 Bern, Switzerland; (M.H.); (C.K.); (J.T.H.)
- Department of Diagnostic, Interventional and Pediatric Radiology, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland
| | - Julien Furrer
- Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland; (V.S.); (O.D.); (T.F.)
| | - Emilia Păunescu
- Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland; (V.S.); (O.D.); (T.F.)
| |
Collapse
|
12
|
Yang P, Zhang DD, Wang ZZ, Liu HZ, Shi QS, Xie XB. Copper(ii) complexes with NNO ligands: synthesis, crystal structures, DNA cleavage, and anticancer activities. Dalton Trans 2019; 48:17925-17935. [PMID: 31793567 DOI: 10.1039/c9dt03746b] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Three novel copper(ii) complexes, Cu(L1)2 (1), Cu(L2)2·2DMF (2), and Cu(L3)2·2DMF (3), were synthesized using three aroylhydrazone ligands, (E)-2-hydroxy-N'-(1-(pyrazin-2-yl)ethylidene)benzohydrazide (HL1), (E)-3-hydroxy-N'-(1-(pyrazin-2-yl)ethylidene)benzohydrazide (HL2) and (E)-4-hydroxy-N'-(1-(pyrazin-2-yl)ethylidene)benzohydrazide (HL3). The complexes were characterized by elemental analysis, infrared (IR), and Ultraviolet-visible light (UV-vis) spectroscopy. The X-ray crystal structures of the complexes all possess a distorted octahedral coordination geometry. Both an absorption spectral titration and a competitive binding assay (ethidium bromide, 4',6-diamidino-2-phenylindole (DAPI), and methyl green) revealed that complexes 2 and 3 bind readily to calf thymus DNA (ctDNA) through intercalative and minor groove binding modes. Complexes 2 and 3 also exhibited oxidative cleavage of supercoiled plasmid DNA (pUC19) in the presence of ascorbic acid as an activator. Cytotoxicity studies showed that complexes 2 and 3 possessed high cytotoxicities toward the HeLa human cervical cancer cell line, but weak toxicities toward the L929 normal mouse fibroblast cell line. We therefore have reason to believe that complexes 2 and 3 both show potential as promising anticancer candidate drugs.
Collapse
Affiliation(s)
- Ping Yang
- Guangdong Institute of Microbiology, Guangdong Academy of Sciences, State Key Laboratory of Applied Microbiology Southern China, Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Open Laboratory of Applied Microbiology, Guangzhou 510070, China.
| | - Dan-Dan Zhang
- Guangdong Institute of Microbiology, Guangdong Academy of Sciences, State Key Laboratory of Applied Microbiology Southern China, Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Open Laboratory of Applied Microbiology, Guangzhou 510070, China.
| | - Zi-Zhou Wang
- School of Chemistry and Chemical Engineering, Guangzhou University, Guangzhou Higher Education Mega Center, 230 Wai Huan Xi Road, Guangzhou 510006, China
| | - Hui-Zhong Liu
- Guangdong Institute of Microbiology, Guangdong Academy of Sciences, State Key Laboratory of Applied Microbiology Southern China, Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Open Laboratory of Applied Microbiology, Guangzhou 510070, China.
| | - Qing-Shan Shi
- Guangdong Institute of Microbiology, Guangdong Academy of Sciences, State Key Laboratory of Applied Microbiology Southern China, Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Open Laboratory of Applied Microbiology, Guangzhou 510070, China.
| | - Xiao-Bao Xie
- Guangdong Institute of Microbiology, Guangdong Academy of Sciences, State Key Laboratory of Applied Microbiology Southern China, Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Open Laboratory of Applied Microbiology, Guangzhou 510070, China.
| |
Collapse
|
13
|
|
14
|
van Niekerk A, Chellan P, Mapolie SF. Heterometallic Multinuclear Complexes as Anti-Cancer Agents-An Overview of Recent Developments. Eur J Inorg Chem 2019. [DOI: 10.1002/ejic.201900375] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Annick van Niekerk
- Department of Chemistry and Polymer Science; Stellenbosch University; Private bag X1, Matieland 7602 Stellenbosch South Africa
| | - Prinessa Chellan
- Department of Chemistry and Polymer Science; Stellenbosch University; Private bag X1, Matieland 7602 Stellenbosch South Africa
| | - Selwyn F. Mapolie
- Department of Chemistry and Polymer Science; Stellenbosch University; Private bag X1, Matieland 7602 Stellenbosch South Africa
| |
Collapse
|
15
|
Pötsch I, Baier D, Keppler BK, Berger W. Challenges and Chances in the Preclinical to Clinical Translation of Anticancer Metallodrugs. METAL-BASED ANTICANCER AGENTS 2019. [DOI: 10.1039/9781788016452-00308] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Despite being “sentenced to death” for quite some time, anticancer platinum compounds are still the most frequently prescribed cancer therapies in the oncological routine and recent exciting news from late-stage clinical studies on combinations of metallodrugs with immunotherapies suggest that this situation will not change soon. It is perhaps surprising that relatively simple molecules like cisplatin, discovered over 50 years ago, are still widely used clinically, while none of the highly sophisticated metal compounds developed over the last decade, including complexes with targeting ligands and multifunctional (nano)formulations, have managed to obtain clinical approval. In this book chapter, we summarize the current status of ongoing clinical trials for anticancer metal compounds and discuss the reasons for previous failures, as well as new opportunities for the clinical translation of metal complexes.
Collapse
Affiliation(s)
- Isabella Pötsch
- University of Vienna, Department of Inorganic Chemistry Währingerstrasse Vienna 1090 Austria
- Medical University of Vienna, Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I Borschkegasse 8a 1090 Vienna Austria
| | - Dina Baier
- University of Vienna, Department of Inorganic Chemistry Währingerstrasse Vienna 1090 Austria
- Medical University of Vienna, Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I Borschkegasse 8a 1090 Vienna Austria
| | - Bernhard K. Keppler
- University of Vienna, Department of Inorganic Chemistry Währingerstrasse Vienna 1090 Austria
| | - Walter Berger
- Medical University of Vienna, Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I Borschkegasse 8a 1090 Vienna Austria
| |
Collapse
|
16
|
Novakova O, Farrell NP, Brabec V. Translesion DNA synthesis across double-base lesions derived from cross-links of an antitumor trinuclear platinum compound: primer extension, conformational and thermodynamic studies. Metallomics 2019; 10:132-144. [PMID: 29242879 DOI: 10.1039/c7mt00266a] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Polynuclear platinum complexes represent a unique structural class of DNA-binding agents of biological significance. They contain at least two platinum coordinating units bridged by a linker, which means that the formation of double-base lesions (cross-links) in DNA is possible. Here, we show that the lead compound, bifunctional [{trans-PtCl(NH3)2}2μ-trans-Pt(NH3)2{H2N(CH2)6NH2}2]4+ (Triplatin or BBR3464), forms in DNA specific double-base lesions which affect the biophysical and biochemical properties of DNA in a way fundamentally different compared to the analogous double-base lesions formed by two adducts of monofunctional chlorodiethylenetriamineplatinum(ii) chloride (dienPt). We find concomitantly that translesion DNA synthesis by the model A-family polymerase, the exonuclease deficient Klenow fragment, across the double-base lesions derived from the intrastrand CLs of Triplatin was markedly less extensive than that across the two analogous monofunctional adducts of dienPt. Collectively, these data provide convincing support for the hypothesis that the central noncovalent tetraamine platinum linker of Triplatin, capable of hydrogen-bonding and electrostatic interactions with DNA and bridging the two platinum adducts, represents an important factor responsible for the markedly lowered tolerance of DNA double-base adducts of Triplatin by DNA polymerases.
Collapse
Affiliation(s)
- O Novakova
- Institute of Biophysics, Czech Academy of Sciences, Kralovopolska 135, CZ-61265 Brno, Czech Republic.
| | | | | |
Collapse
|
17
|
Kenny RG, Marmion CJ. Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens? Chem Rev 2019; 119:1058-1137. [PMID: 30640441 DOI: 10.1021/acs.chemrev.8b00271] [Citation(s) in RCA: 390] [Impact Index Per Article: 78.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
While medicinal inorganic chemistry has been practised for over 5000 years, it was not until the late 1800s when Alfred Werner published his ground-breaking research on coordination chemistry that we began to truly understand the nature of the coordination bond and the structures and stereochemistries of metal complexes. We can now readily manipulate and fine-tune their properties. This had led to a multitude of complexes with wide-ranging biomedical applications. This review will focus on the use and potential of metal complexes as important therapeutic agents for the treatment of cancer. With major advances in technologies and a deeper understanding of the human genome, we are now in a strong position to more fully understand carcinogenesis at a molecular level. We can now also rationally design and develop drug molecules that can either selectively enhance or disrupt key biological processes and, in doing so, optimize their therapeutic potential. This has heralded a new era in drug design in which we are moving from a single- toward a multitargeted approach. This approach lies at the very heart of medicinal inorganic chemistry. In this review, we have endeavored to showcase how a "multitargeted" approach to drug design has led to new families of metallodrugs which may not only reduce systemic toxicities associated with modern day chemotherapeutics but also address resistance issues that are plaguing many chemotherapeutic regimens. We have focused our attention on metallodrugs incorporating platinum and ruthenium ions given that complexes containing these metal ions are already in clinical use or have advanced to clinical trials as anticancer agents. The "multitargeted" complexes described herein not only target DNA but also contain either vectors to enable them to target cancer cells selectively and/or moieties that target enzymes, peptides, and intracellular proteins. Multitargeted complexes which have been designed to target the mitochondria or complexes inspired by natural product activity are also described. A summary of advances in this field over the past decade or so will be provided.
Collapse
Affiliation(s)
- Reece G Kenny
- Centre for Synthesis and Chemical Biology, Department of Chemistry , Royal College of Surgeons in Ireland , 123 St. Stephen's Green , Dublin 2 , Ireland
| | - Celine J Marmion
- Centre for Synthesis and Chemical Biology, Department of Chemistry , Royal College of Surgeons in Ireland , 123 St. Stephen's Green , Dublin 2 , Ireland
| |
Collapse
|
18
|
Parveen S, Hanif M, Leung E, Tong KKH, Yang A, Astin J, De Zoysa GH, Steel TR, Goodman D, Movassaghi S, Söhnel T, Sarojini V, Jamieson SMF, Hartinger CG. Anticancer organorhodium and -iridium complexes with low toxicity in vivo but high potency in vitro: DNA damage, reactive oxygen species formation, and haemolytic activity. Chem Commun (Camb) 2019; 55:12016-12019. [DOI: 10.1039/c9cc03822a] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Dinuclear RhIII(Cp*) and IrIII(Cp*) complexes demonstrated potent in vitro anticancer activity while exhibiting low toxicity in haemolysis studies and in vivo zebrafish models.
Collapse
Affiliation(s)
- Shahida Parveen
- School of Chemical Sciences
- University of Auckland
- Auckland 1142
- New Zealand
| | - Muhammad Hanif
- School of Chemical Sciences
- University of Auckland
- Auckland 1142
- New Zealand
| | - Euphemia Leung
- Auckland Cancer Society Research Centre
- University of Auckland
- Auckland 1142
- New Zealand
| | - Kelvin K. H. Tong
- School of Chemical Sciences
- University of Auckland
- Auckland 1142
- New Zealand
| | - Annie Yang
- Department of Molecular Medicine and Pathology
- University of Auckland
- Auckland 1142
- New Zealand
| | - Jonathan Astin
- Department of Molecular Medicine and Pathology
- University of Auckland
- Auckland 1142
- New Zealand
| | - Gayan H. De Zoysa
- School of Chemical Sciences
- University of Auckland
- Auckland 1142
- New Zealand
| | - Tasha R. Steel
- School of Chemical Sciences
- University of Auckland
- Auckland 1142
- New Zealand
| | - David Goodman
- School of Chemical Sciences
- University of Auckland
- Auckland 1142
- New Zealand
| | - Sanam Movassaghi
- School of Chemical Sciences
- University of Auckland
- Auckland 1142
- New Zealand
| | - Tilo Söhnel
- School of Chemical Sciences
- University of Auckland
- Auckland 1142
- New Zealand
| | | | | | | |
Collapse
|
19
|
In vitro antitumour activity of two ferrocenyl metallodendrimers in a colon cancer cell line. INORG CHEM COMMUN 2018. [DOI: 10.1016/j.inoche.2018.09.042] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
20
|
Xiao H, Yan L, Dempsey EM, Song W, Qi R, Li W, Huang Y, Jing X, Zhou D, Ding J, Chen X. Recent progress in polymer-based platinum drug delivery systems. Prog Polym Sci 2018. [DOI: 10.1016/j.progpolymsci.2018.07.004] [Citation(s) in RCA: 105] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
21
|
Shi H, Romero-Canelón I, Hreusova M, Novakova O, Venkatesh V, Habtemariam A, Clarkson GJ, Song JI, Brabec V, Sadler PJ. Photoactivatable Cell-Selective Dinuclear trans-Diazidoplatinum(IV) Anticancer Prodrugs. Inorg Chem 2018; 57:14409-14420. [PMID: 30365308 PMCID: PMC6257630 DOI: 10.1021/acs.inorgchem.8b02599] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
![]()
A series of dinuclear
octahedral PtIV complexes trans,trans,trans-[{Pt(N3)2(py)2(OH)(OC(O)CH2CH2C(O)NH)}2R] containing pyridine (py) and bridging
dicarboxylate [R = −CH2CH2– (1), trans-1,2-C6H10– (2), p-C6H4– (3), −CH2CH2CH2CH2– (4)] ligands have
been synthesized and characterized, including the X-ray crystal structures
of complexes 1·2MeOH and 4, the first
photoactivatable dinuclear PtIV complexes with azido ligands.
The complexes are highly stable in the dark, but upon photoactivation
with blue light (420 nm), they release the bridging ligand and mononuclear
photoproducts. Upon irradiation with blue light (465 nm), they generate
azidyl and hydroxyl radicals, detected using a 5,5-dimethyl-1-pyrroline N-oxide electron paramagnetic resonance spin trap, accompanied
by the disappearance of the ligand-to-metal charge-transfer (N3 → Pt) band at ca. 300 nm. The dinuclear complexes
are photocytotoxic to human cancer cells (465 nm, 4.8 mW/cm2, 1 h), including A2780 human ovarian and esophageal OE19 cells with
IC50 values of 8.8–78.3 μM, whereas cisplatin
is inactive under these conditions. Complexes 1, 3, and 4 are notably more photoactive toward
cisplatin-resistant ovarian A2780cis compared to A2780 cells. Remarkably,
all of the complexes were relatively nontoxic toward normal cells
(MRC5 lung fibroblasts), with IC50 values >100 μM,
even after irradiation. The introduction of an aromatic bridging ligand
(3) significantly enhanced cellular uptake. The populations
in the stages of the cell cycle remained unchanged upon treatment
with complexes in the dark, while the population of the G2/M phase
increased upon irradiation, suggesting that DNA is a target for these
photoactivated dinuclear PtIV complexes. Liquid chromatography–mass
spectrometry data show that the photodecomposition pathway of the
dinuclear complexes results in the release of two molecules of mononuclear
platinum(II) species. As a consequence, DNA binding of the dinuclear
complexes after photoactivation in cell-free media is, in several
respects, qualitatively similar to that of the photoactivated mononuclear
complex FM-190. After photoactivation, they were 2-fold
more effective in quenching the fluorescence of EtBr bound to DNA,
forming DNA interstrand cross-links and unwinding DNA compared to
the photoactivated FM-190. Novel all-trans dinuclear
PtIV complexes bridged
by a dicarboxylate linker, highly stable in the dark, generate azidyl
and hydroxyl radicals upon irradiation with blue light. They are photocytotoxic
to human cancer cells, whereas cisplatin was inactive under these
conditions and more photoactive toward cisplatin-resistant ovarian
cancer cells compared to wild-type cells. Remarkably, the dinuclear
complexes were relatively nontoxic toward normal human cells. Cell
cycle and DNA binding experiments suggested that DNA is a target.
Collapse
Affiliation(s)
- Huayun Shi
- Department of Chemistry , University of Warwick , Coventry CV4 7AL , U.K
| | - Isolda Romero-Canelón
- Department of Chemistry , University of Warwick , Coventry CV4 7AL , U.K.,School of Pharmacy, Institute of Clinical Sciences , University of Birmingham , Birmingham B15 2TT , U.K
| | - Monika Hreusova
- Department of Biophysics, Faculty of Science , Palacky University , 17 listopadu 12 , Olomouc CZ-77146 , Czech Republic.,Institute of Biophysics , Czech Academy of Sciences , Kralovopolska 135 , Brno CZ-61265 , Czech Republic
| | - Olga Novakova
- Institute of Biophysics , Czech Academy of Sciences , Kralovopolska 135 , Brno CZ-61265 , Czech Republic
| | - V Venkatesh
- Department of Chemistry , University of Warwick , Coventry CV4 7AL , U.K
| | - Abraha Habtemariam
- Department of Chemistry , University of Warwick , Coventry CV4 7AL , U.K
| | - Guy J Clarkson
- Department of Chemistry , University of Warwick , Coventry CV4 7AL , U.K
| | - Ji-Inn Song
- Department of Chemistry , University of Warwick , Coventry CV4 7AL , U.K
| | - Viktor Brabec
- Institute of Biophysics , Czech Academy of Sciences , Kralovopolska 135 , Brno CZ-61265 , Czech Republic
| | - Peter J Sadler
- Department of Chemistry , University of Warwick , Coventry CV4 7AL , U.K
| |
Collapse
|
22
|
Cai L, Yu C, Ba L, Liu Q, Qian Y, Yang B, Gao C. Anticancer platinum-based complexes with non-classical structures. Appl Organomet Chem 2018. [DOI: 10.1002/aoc.4228] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Linxiang Cai
- Faculty of Life Science and Technology; Kunming University of Science and Technology; Kunming 650500 China
| | - Congtao Yu
- Faculty of Life Science and Technology; Kunming University of Science and Technology; Kunming 650500 China
| | - Linkui Ba
- Faculty of Life Science and Technology; Kunming University of Science and Technology; Kunming 650500 China
| | - Qinghua Liu
- Faculty of Life Science and Technology; Kunming University of Science and Technology; Kunming 650500 China
| | - Yunxu Qian
- Faculty of Life Science and Technology; Kunming University of Science and Technology; Kunming 650500 China
| | - Bo Yang
- Faculty of Life Science and Technology; Kunming University of Science and Technology; Kunming 650500 China
| | - Chuanzhu Gao
- Faculty of Life Science and Technology; Kunming University of Science and Technology; Kunming 650500 China
| |
Collapse
|
23
|
Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans 2018; 47:6645-6653. [DOI: 10.1039/c8dt00838h] [Citation(s) in RCA: 706] [Impact Index Per Article: 117.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The platinum chemotherapy drugs cisplatin, carboplatin, and oxaliplatin are known to cause seven different types of side effects in patients.
Collapse
|
24
|
|
25
|
Brabec V, Hrabina O, Kasparkova J. Cytotoxic platinum coordination compounds. DNA binding agents. Coord Chem Rev 2017. [DOI: 10.1016/j.ccr.2017.04.013] [Citation(s) in RCA: 77] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
26
|
Batchelor LK, Păunescu E, Soudani M, Scopelliti R, Dyson PJ. Influence of the Linker Length on the Cytotoxicity of Homobinuclear Ruthenium(II) and Gold(I) Complexes. Inorg Chem 2017; 56:9617-9633. [DOI: 10.1021/acs.inorgchem.7b01082] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Lucinda K. Batchelor
- Institut des Sciences et Ingénierie
Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
| | - Emilia Păunescu
- Institut des Sciences et Ingénierie
Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
| | - Mylène Soudani
- Institut des Sciences et Ingénierie
Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
| | - Rosario Scopelliti
- Institut des Sciences et Ingénierie
Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
| | - Paul J. Dyson
- Institut des Sciences et Ingénierie
Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
| |
Collapse
|
27
|
Lazarević T, Rilak A, Bugarčić ŽD. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives. Eur J Med Chem 2017; 142:8-31. [PMID: 28442170 DOI: 10.1016/j.ejmech.2017.04.007] [Citation(s) in RCA: 260] [Impact Index Per Article: 37.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2017] [Revised: 03/30/2017] [Accepted: 04/03/2017] [Indexed: 11/18/2022]
Abstract
Metallodrugs offer potential for unique mechanism of drug action based on the choice of the metal, its oxidation state, the types and number of coordinated ligands and the coordination geometry. This review illustrates notable recent progress in the field of medicinal bioinorganic chemistry as many new approaches to the design of innovative metal-based anticancer drugs are emerging. Current research addressing the problems associated with platinum drugs has focused on other metal-based therapeutics that have different modes of action and on prodrug and targeting strategies in an effort to diminish the side-effects of cisplatin chemotherapy. Examples of metal compounds and chelating agents currently in clinical use, clinical trials or preclinical development are highlighted.
Collapse
Affiliation(s)
- Tatjana Lazarević
- University of Kragujevac, Faculty of Medicine, S. Marković 69, 34000, Kragujevac, Serbia
| | - Ana Rilak
- University of Kragujevac, Faculty of Science, R. Domanovića 12, P. O. Box 60, 34000 Kragujevac, Serbia.
| | - Živadin D Bugarčić
- University of Kragujevac, Faculty of Science, R. Domanovića 12, P. O. Box 60, 34000 Kragujevac, Serbia.
| |
Collapse
|
28
|
The Role of an Alkyl-Phenyl Spacer on the Reactivity of Novel Platinum(II) Complexes with Thiourea Nucleophiles. INT J CHEM KINET 2017. [DOI: 10.1002/kin.21085] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
29
|
Parker JP, Ude Z, Marmion CJ. Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer. Metallomics 2016; 8:43-60. [PMID: 26567482 DOI: 10.1039/c5mt00181a] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Platinum drugs as anti-cancer therapeutics are held in extremely high regard. Despite their success, there are drawbacks associated with their use; their dose-limiting toxicity, their limited activity against an array of common cancers and patient resistance to Pt-based therapeutic regimes. Current investigations in medicinal inorganic chemistry strive to offset these shortcomings through selective targeting of Pt drugs and/or the development of Pt drugs with new or multiple modes of action. A comprehensive overview showcasing how liposomes, nanocapsules, polymers, dendrimers, nanoparticles and nanotubes may be employed as vehicles to selectively deliver cytotoxic Pt payloads to tumour cells is provided.
Collapse
Affiliation(s)
- James P Parker
- Centre for Synthesis and Chemical Biology, Department of Pharmaceutical & Medicinal Chemistry, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland.
| | - Ziga Ude
- Centre for Synthesis and Chemical Biology, Department of Pharmaceutical & Medicinal Chemistry, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland.
| | - Celine J Marmion
- Centre for Synthesis and Chemical Biology, Department of Pharmaceutical & Medicinal Chemistry, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland.
| |
Collapse
|
30
|
Jastrząb R, Łomozik L, Tylkowski B. Complexes of biogenic amines in their role in living systems. PHYSICAL SCIENCES REVIEWS 2016. [DOI: 10.1515/psr-2016-0003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
31
|
Johnstone TC, Suntharalingam K, Lippard SJ. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem Rev 2016; 116:3436-86. [PMID: 26865551 PMCID: PMC4792284 DOI: 10.1021/acs.chemrev.5b00597] [Citation(s) in RCA: 1654] [Impact Index Per Article: 206.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic. Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs. The use of nanodelivery devices has also grown, and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs. In this Review, we discuss these efforts to create the next generation of platinum anticancer drugs. The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished. We then describe approaches that explore nonclassical platinum(II) complexes with trans geometry or with a monofunctional coordination mode, polynuclear platinum(II) compounds, platinum(IV) prodrugs, dual-threat agents, and photoactivatable platinum(IV) complexes. Nanoparticles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles. Additional nanoformulations, including supramolecular self-assembled structures, proteins, peptides, metal-organic frameworks, and coordination polymers, will then be described. Finally, the significant clinical progress made by nanoparticle formulations of platinum(II) agents will be reviewed. We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also will reflect our optimism that the next generation of approved platinum cancer drugs is about to arrive.
Collapse
Affiliation(s)
- Timothy C Johnstone
- Department of Chemistry, Massachusetts Institute of Technology , Cambridge, Massachusetts 02139, United States
| | | | - Stephen J Lippard
- Department of Chemistry, Massachusetts Institute of Technology , Cambridge, Massachusetts 02139, United States
| |
Collapse
|
32
|
Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol 2016; 77:1103-24. [PMID: 26886018 DOI: 10.1007/s00280-016-2976-z] [Citation(s) in RCA: 515] [Impact Index Per Article: 64.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2015] [Accepted: 01/20/2016] [Indexed: 12/22/2022]
Abstract
Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of human neoplasms. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Much effort has been put into the development of new platinum anticancer complexes, but none of them has reached worldwide clinical application so far. Nedaplatin, lobaplatin and heptaplatin received only regional approval. Some new platinum complexes and platinum drug formulations are undergoing clinical trials. Here, we review the main classes of new platinum drug candidates, such as sterically hindered complexes, monofunctional platinum drugs, complexes with biologically active ligands, trans-configured and polynuclear platinum complexes, platinum(IV) prodrugs and platinum-based drug delivery systems. For each class of compounds, a detailed overview of the mechanism of action is given, the cytotoxicity is compared to that of the clinically used platinum drugs, and the clinical perspectives are discussed. A critical analysis of lessons to be learned is presented. Finally, a general outlook regarding future directions in the field of new platinum drugs is given.
Collapse
|
33
|
Abstract
Cisplatin and other platinum compounds have had a huge impact in the treatment of cancers and are applied in the majority of anticancer chemotherapeutic regimens. The success of these compounds has biased the approaches used to discover new metal-based anticancer drugs. In this perspective we highlight compounds that are apparently incompatible with the more classical (platinum-derived) concepts employed in the development of metal-based anticancer drugs, with respect to both compound design and the approaches used to validate their utility. Possible design approaches for the future are also suggested.
Collapse
Affiliation(s)
- Claire S Allardyce
- Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
| | | |
Collapse
|
34
|
Target-selective delivery and activation of platinum-based anticancer agents. Future Med Chem 2015; 7:911-27. [DOI: 10.4155/fmc.15.37] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
|
35
|
Pages BJ, Ang DL, Wright EP, Aldrich-Wright JR. Metal complex interactions with DNA. Dalton Trans 2015; 44:3505-26. [DOI: 10.1039/c4dt02700k] [Citation(s) in RCA: 241] [Impact Index Per Article: 26.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Increasing numbers of DNA structures are being revealed using a diverse range of transition metal complexes and biophysical spectroscopic techniques. Here we present a review of metal complex-DNA interactions in which several binding modes and DNA structural forms are explored.
Collapse
Affiliation(s)
- Benjamin J. Pages
- Nanoscale Organisation and Dynamics Group
- School of Science and Health
- University of Western Sydney
- Locked Bag 1797 Penrith South DC
- Australia
| | - Dale L. Ang
- Nanoscale Organisation and Dynamics Group
- School of Science and Health
- University of Western Sydney
- Locked Bag 1797 Penrith South DC
- Australia
| | - Elisé P. Wright
- School of Medicine
- University of Western Sydney
- Locked Bag 1797 Penrith South DC
- Australia
| | - Janice R. Aldrich-Wright
- Nanoscale Organisation and Dynamics Group
- School of Science and Health
- University of Western Sydney
- Locked Bag 1797 Penrith South DC
- Australia
| |
Collapse
|
36
|
Wenzel M, Bigaeva E, Richard P, Le Gendre P, Picquet M, Casini A, Bodio E. New heteronuclear gold(I)-platinum(II) complexes with cytotoxic properties: are two metals better than one? J Inorg Biochem 2014; 141:10-16. [PMID: 25172993 DOI: 10.1016/j.jinorgbio.2014.07.011] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2014] [Revised: 07/11/2014] [Accepted: 07/14/2014] [Indexed: 11/19/2022]
Abstract
A series of mono- and heterodinuclear gold(I) and platinum(II) complexes with a new bipyridylamine-phosphine ligand have been synthesized and characterized. The X-ray structures of the ligand precursor 4-iodo-N,N-di(pyridin-2-yl)benzamide, and of one gold derivative are reported. All the complexes display antiproliferative properties in vitro in human cancer cells in the range of cisplatin or higher, which appear to correlate with compounds' uptake. Interestingly, studies of the interactions of the compounds with models of DNA indicate different mechanisms of actions with respect to cisplatin. The biological activity study of these complexes provides useful information about the interest of designing multimetallic complexes for enhanced cytotoxic properties.
Collapse
Affiliation(s)
- Margot Wenzel
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302 CNRS, Université de Bourgogne, 9 avenue A. Savary, BP47870, 21078 Dijon, France
| | - Emilia Bigaeva
- Dept. Pharmacokinetics, Toxicology and Targeting, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
| | - Philippe Richard
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302 CNRS, Université de Bourgogne, 9 avenue A. Savary, BP47870, 21078 Dijon, France
| | - Pierre Le Gendre
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302 CNRS, Université de Bourgogne, 9 avenue A. Savary, BP47870, 21078 Dijon, France
| | - Michel Picquet
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302 CNRS, Université de Bourgogne, 9 avenue A. Savary, BP47870, 21078 Dijon, France
| | - Angela Casini
- Dept. Pharmacokinetics, Toxicology and Targeting, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
| | - Ewen Bodio
- Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302 CNRS, Université de Bourgogne, 9 avenue A. Savary, BP47870, 21078 Dijon, France.
| |
Collapse
|
37
|
Abstract
This review article covers the synthetic strategies, structural aspects, and host-guest properties of ruthenium metalla-assemblies, with a special focus on their use as drug delivery vectors. The two-dimensional metalla-rectangles show interesting host-guest possibilities but seem less appropriate for being used as drug carriers. On the other hand, metalla-prisms allow encapsulation and possible targeted release of bioactive molecules and consequently show some potential as drug delivery vectors. The reactivity of these metalla-prisms can be fine-tuned to allow a fine control of the guest’s release. The larger metalla-cubes can be used to stabilize the formation of G-quadruplex DNA and can be used to encapsulate and release photoactive molecules such as porphins. These metalla-assemblies demonstrate great prospective in photodynamic therapy.
Collapse
|
38
|
Apps MG, Johnson BW, Sutcliffe OB, Brown SD, Wheate NJ. Amide coupling reaction for the synthesis of bispyridine-based ligands and their complexation to platinum as dinuclear anticancer agents. J Vis Exp 2014. [PMID: 24893964 DOI: 10.3791/51740] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
Amide coupling reactions can be used to synthesize bispyridine-based ligands for use as bridging linkers in multinuclear platinum anticancer drugs. Isonicotinic acid, or its derivatives, are coupled to variable length diaminoalkane chains under an inert atmosphere in anhydrous DMF or DMSO with the use of a weak base, triethylamine, and a coupling agent, 1-propylphosphonic anhydride. The products precipitate from solution upon formation or can be precipitated by the addition of water. If desired, the ligands can be further purified by recrystallization from hot water. Dinuclear platinum complex synthesis using the bispyridine ligands is done in hot water using transplatin. The most informative of the chemical characterization techniques to determine the structure and gross purity of both the bispyridine ligands and the final platinum complexes is (1)H NMR with particular analysis of the aromatic region of the spectra (7-9 ppm). The platinum complexes have potential application as anticancer agents and the synthesis method can be modified to produce trinuclear and other multinuclear complexes with different hydrogen bonding functionality in the bridging ligand.
Collapse
Affiliation(s)
| | - Ben W Johnson
- School of Science and Health, University of Western Sydney
| | - Oliver B Sutcliffe
- Division of Chemistry and Environmental Science, School of Science and the Environment, Manchester Metropolitan University
| | | | | |
Collapse
|
39
|
Motswainyana WM, Onani MO, Madiehe AM, Saibu M. Antitumor activity of phenylene bridged binuclear bis(imino-quinolyl)palladium(II) and platinum(II) complexes. Bioorg Med Chem Lett 2014; 24:1692-4. [DOI: 10.1016/j.bmcl.2014.02.056] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2013] [Revised: 02/18/2014] [Accepted: 02/20/2014] [Indexed: 12/16/2022]
|
40
|
Detailed mechanistic study on ligand substitution reactions in dinuclear platinum(II) complexes: effect of alkanediamine linker. TRANSIT METAL CHEM 2014. [DOI: 10.1007/s11243-014-9815-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
41
|
Nazarov AA, Hartinger CG, Dyson PJ. Opening the lid on piano-stool complexes: An account of ruthenium(II)–arene complexes with medicinal applications. J Organomet Chem 2014. [DOI: 10.1016/j.jorganchem.2013.09.016] [Citation(s) in RCA: 209] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
42
|
Malina J, Farrell NP, Brabec V. DNA Condensing Effects and Sequence Selectivity of DNA Binding of Antitumor Noncovalent Polynuclear Platinum Complexes. Inorg Chem 2014; 53:1662-71. [DOI: 10.1021/ic402796k] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- Jaroslav Malina
- Institute
of Biophysics, Academy of Sciences of the Czech Republic, v.v.i.,
Kralovopolska 135, CZ-61265 Brno, Czech Republic
| | - Nicholas P. Farrell
- Department
of Chemistry, Virginia Commonwealth University, Richmond, Virginia 23284-2006, United States
| | - Viktor Brabec
- Institute
of Biophysics, Academy of Sciences of the Czech Republic, v.v.i.,
Kralovopolska 135, CZ-61265 Brno, Czech Republic
| |
Collapse
|
43
|
Govender P, Edafe F, Makhubela BC, Dyson PJ, Therrien B, Smith GS. Neutral and cationic osmium(II)-arene metallodendrimers: Synthesis, characterisation and anticancer activity. Inorganica Chim Acta 2014. [DOI: 10.1016/j.ica.2013.05.025] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
44
|
Gorle AK, Ammit AJ, Wallace L, Keene FR, Collins JG. Multinuclear ruthenium(ii) complexes as anticancer agents. NEW J CHEM 2014. [DOI: 10.1039/c4nj00545g] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The dinuclear ruthenium complex with X = H is four-times more cytotoxic than cisplatin against breast cancer cell lines; however, when X = NO2 the ruthenium complex is less active than cisplatin.
Collapse
Affiliation(s)
- Anil K. Gorle
- School of Physical
- Environmental and Mathematical Sciences
- University of New South Wales
- Australian Defence Force Academy
- Canberra, Australia
| | - Alaina J. Ammit
- Faculty of Pharmacy
- The University of Sydney
- Sydney, Australia
| | - Lynne Wallace
- School of Physical
- Environmental and Mathematical Sciences
- University of New South Wales
- Australian Defence Force Academy
- Canberra, Australia
| | - F. Richard Keene
- Centre for Biodiscovery and Molecular Development of Therapeutics
- James Cook University
- Townsville, Australia
- School of Pharmacy and Molecular Sciences
- James Cook University
| | - J. Grant Collins
- School of Physical
- Environmental and Mathematical Sciences
- University of New South Wales
- Australian Defence Force Academy
- Canberra, Australia
| |
Collapse
|
45
|
Marín MJ, Rackham BD, Round AN, Howell LA, Russell DA, Searcey M. A rapid screen for molecules that form duplex to duplex crosslinks in DNA. Chem Commun (Camb) 2013; 49:9113-5. [PMID: 23995794 DOI: 10.1039/c3cc45600e] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We describe a gold nanoparticle based assay that can rapidly determine the crosslinking of DNA duplexes by ligands. Such compounds have potential in targeting highly compacted DNA such as that found in the nucleosome.
Collapse
Affiliation(s)
- María J Marín
- School of Chemistry, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK.
| | | | | | | | | | | |
Collapse
|
46
|
Platinum and Palladium Polyamine Complexes as Anticancer Agents: The Structural Factor. ACTA ACUST UNITED AC 2013. [DOI: 10.1155/2013/287353] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Since the introduction of cisplatin to oncology in 1978, Pt(II) and Pd(II) compounds have been intensively studied with a view to develop the improved anticancer agents. Polynuclear polyamine complexes, in particular, have attracted special attention, since they were found to yield DNA adducts not available to conventional drugs (through long-distance intra- and interstrand cross-links) and to often circumvent acquired cisplatin resistance. Moreover, the cytotoxic potency of these polyamine-bridged chelates is strictly regulated by their structural characteristics, which renders this series of compounds worth investigating and their synthesis being carefully tailored in order to develop third-generation drugs coupling an increased spectrum of activity to a lower toxicity. The present paper addresses the latest developments in the design of novel antitumor agents based on platinum and palladium, particularly polynuclear chelates with variable length aliphatic polyamines as bridging ligands, highlighting the close relationship between their structural preferences and cytotoxic ability. In particular, studies by vibrational spectroscopy techniques are emphasised, allowing to elucidate the structure-activity relationships (SARs) ruling anticancer activity.
Collapse
|
47
|
Xiao H, Song H, Zhang Y, Qi R, Wang R, Xie Z, Huang Y, Li Y, Wu Y, Jing X. The use of polymeric platinum(IV) prodrugs to deliver multinuclear platinum(II) drugs with reduced systemic toxicity and enhanced antitumor efficacy. Biomaterials 2012; 33:8657-69. [PMID: 22938766 DOI: 10.1016/j.biomaterials.2012.08.015] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2012] [Accepted: 08/05/2012] [Indexed: 02/04/2023]
Abstract
Two dinuclear platinum(IV) prodrugs were prepared from cisplatin and oxaliplatin, and tethered to amphiphilic biodegradable block copolymers. The polymeric dinuclear platinum(IV) prodrugs were allowed to self-assemble into nanomicelles, which showed reduced systemic toxicity, relatively long blood circulation, and enhanced antitumor efficacy. In this way, the bottleneck of present multinuclear platinum drugs, especially their severe systemic toxicity, might be overcome.
Collapse
Affiliation(s)
- Haihua Xiao
- State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, People's Republic of China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Hartinger CG, Metzler-Nolte N, Dyson PJ. Challenges and Opportunities in the Development of Organometallic Anticancer Drugs. Organometallics 2012. [DOI: 10.1021/om300373t] [Citation(s) in RCA: 470] [Impact Index Per Article: 39.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Christian G. Hartinger
- School of Chemical Sciences, The University of Auckland, Private
Bag 92019, Auckland 1142, New Zealand
| | - Nils Metzler-Nolte
- Inorganic Chemistry I-Bioinorganic Chemistry, Faculty of Chemistry and Biochemistry, Ruhr University Bochum, Universitaetsstrasse, 44801
Bochum, Germany
| | - Paul J. Dyson
- Institut des Sciences et Ingénierie
Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), EPFL−BCH, CH-1015 Lausanne,
Switzerland
| |
Collapse
|
49
|
Murphy RF, Komlodi-Pasztor E, Robey R, Balis FM, Farrell NP, Fojo T. Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin. Cell Cycle 2012; 11:963-73. [PMID: 22333583 DOI: 10.4161/cc.11.5.19447] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Despite the clinical success of platinum-containing drugs in the treatment of solid tumors, acquired resistance remains a major obstacle. We previously identified a group of novel transplanaramine or transplatinum compounds based on distinct activity profiles in the NCI-60 panel. In the present study, parental KB-3.1 cells with wild-type p53 and its cisplatin- and oxaliplatin-resistant sublines harboring mutant p53 proteins were used to contrast several transplatinum compounds with cisplatin and oxaliplatin. The transplatinum compounds retained cytotoxic activity in the resistant cell lines. While intracellular accumulation and DNA platination of cisplatin and oxaliplatin was decreased in the resistant cells, the transplatinum compounds both accumulated intracellularly and platinated DNA at comparable levels in all cell lines. Cytoflow analysis confirmed that cisplatin and oxaliplatin alter the cell cycle distribution and result in apoptosis; however, at comparably toxic concentrations, the transplatinum compounds did not alter the cell cycle distribution. Analysis of the cytoplasmic fraction treated with acetone showed that cisplatin and oxaliplatin readily bound to macromolecules in the pellet, whereas a larger percentage of the transplatinum compounds remained in the supernatant. We concluded that, distinct from platinum compounds currently in use, transplatinum compounds accumulate intracellularly in resistant cells at levels comparable to those in drug-sensitive cells, do not affect the cell cycle and thus retain cytotoxicity independent of p53 status and likely have cytoplasmic targets that are important in their activity.
Collapse
Affiliation(s)
- Robert F Murphy
- Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, USA.
| | | | | | | | | | | |
Collapse
|
50
|
Banerjee T, Dubey P, Mukhopadhyay R. DNA compaction by mononuclear platinum cancer drug cisplatin and the trisplatinum anticancer agent BBR3464: Differences and similarities. Biochimie 2012; 94:494-502. [DOI: 10.1016/j.biochi.2011.08.018] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2011] [Accepted: 08/24/2011] [Indexed: 10/17/2022]
|